1月29日 - ** Fractyl Health GUTS.O股价盘前下跌62.85%至62美分
** 该公司称，一项小型研究显示，与接受假治疗的患者相比，接受Revita手术治疗的患者在停用常用减肥药后体重反弹较少
** Revita是一种实验性内窥镜手术，它可以改变停用了礼来公司LLY.N重磅减肥药的活性成分利西帕肽（tirzepatide）的患者的部分小肠。
** 该公司称，Revita患者的体重在六个月内恢复了4.5%，而假药组恢复了7.5%。
** 该公司称，将在今年下半年公布更大规模研究的 6 个月最高数据，并可能提出美国市场销售申请
** 2025 年，GUTS 股价上涨 6.8%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.